Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tarlatamab + pembrolizumab
- Development stage
- Phase 1
- Lead developer
- Amgen
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Tarlatamab + pembrolizumab** is an investigational combination therapy comprising tarlatamab, a bispecific T-cell engager (BiTE®) antibody, and pembrolizumab, a humanized monoclonal antibody targeting PD-1. Tarlatamab binds to delta-like ligand 3 (DLL3) on tumor cells and CD3 on T cells, redirecting T lymphocytes to induce cell-mediated cytotoxicity against DLL3-expressing tumor cells, primarily in small cell lung cancer (SCLC)[4][6]. Pembrolizumab, an immune checkpoint inhibitor, binds PD-1 on T cells and blocks its interaction with PD-L1 and PD-L2, reactivating exhausted T-cell responses and promoting antitumor immunity[2]. The combination strategy is currently studied in patients with relapsed/refractory small cell lung cancer (RR SCLC) and extensive-stage SCLC (ES-SCLC) who have progressed after platinum-based chemotherapy, with early-phase trials demonstrating a manageable safety profile and durable efficacy as first-line maintenance in ES-SCLC[1][3][7].
- Other names
- tarlatamabpembrolizumab
02
Targets
CD3 (T-cell surface glycoprotein CD3)DLL3 (Delta-like ligand 3)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on tarlatamab + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tarlatamab + pembrolizumab.